Urologic Disorders Archives - Renal and Urology News

Urologic Disorders

cre-carbapenem-resistant-enter

Novel Antibiotic Combo Beats Piperacillin-Tazobactam in Complicated UTI Trial

The combination of cefepime, a cephalosporin antibiotic, and enmetazobactam, a novel extended-spectrum β-lactamase inhibitor (Exblifep; Allecra Therapeutics) was found to be superior to piperacillin-tazobactam in the treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis, according to top-line results from the phase 3 ALLIUM trial. The double-blind, non-inferiority study included 1034 patients randomized to…

urine sample

Contepo NDA for Complicated UTI Resubmitted

Fosfomycin is a novel, epoxide intravenous antibiotic with a broad spectrum of Gram-negative and Gram-positive activity, including activity against multi-drug resistant (MDR) strains such as extended spectrum β-lactamase (ESBL)-producing Enterobacteriaceae.

Risk of Acute Kidney Injury With SGLT2 Inhibitors Investigated

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) do not appear to increase the risk of acute kidney injury (AKI), according to the findings of a recently published systematic review and meta-analysis. To evaluate the risk of AKI with these agents, study authors reviewed literature analyzing the effect of SGLT2is on renal adverse events compared with placebo or other…

Renal Impairment Labeling Updates for Sofosbuvir-Based HCV Therapies

The FDA has approved updated labeling for Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir) and Vosevi (sofosbuvir/velpatasvir/voxilaprevir) to include updated information regarding treatment of patients with hepatitis C virus (HCV) who have severe renal impairment including those with end stage renal disease who are on dialysis.

Next post in Uncategorized